(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

USO DE LACTAMA

ConcedidaInvention PatentPCT · EP2017067783

Application data

Number

112019001127

Type

Invention Patent

Filing

07/13/2017

Publication

04/30/2019

PCT

EP2017067783

Progress at the INPI

  1. Filing07/13/17
  2. Publication04/30/19
  3. Examination
  4. Allowance05/21/24
  5. Grant07/02/24
  6. In force07/13/37

The patent was granted on 07/02/2024 and is in force until 07/13/2037. Until then, no one may make, use or sell the invention in Brazil without the owner's authorisation.

Protection valid until:07/13/2037

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 07/02/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

UNILEVER IP HOLDINGS B.V.

PB

UNILEVER N.V.

NL

See this company's full portfolio

Inventors

N. P. (pessoa física)

GB

P. P. (pessoa física)

GB

P. W. (pessoa física)

GB

Technical data

Priority claims

EP

16180590.8 · 07/21/2016

Abstract

A presente invenção refere-se a 4-(4-clorofenil)-5-metileno-pirrol-2-ona e 5-metileno-4-(p-tolil)pirrol-2-ona para o uso no tratamento de infecções bacterianas gram-negativas, em particular infecções nas quais Pseudomonas está implicada.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Concessão da patente

#16.1

Prazo de Validade: 20 (vinte) anos contados a partir de 13/07/2017, observadas as condições legais

07/02/2024

RPI 2791

Deferimento

#9.1

05/21/2024

RPI 2785

Parecer de pré-exame

#6.23

10/13/2021

RPI 2649

Transferência deferida

#25.1

02/09/2021

RPI 2614

Notificação de entrada na fase nacional - PCT

#1.3

04/30/2019

RPI 2521

Alteração de dados cadastrais

#1.1

01/29/2019

RPI 2508

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.